Background. Plasma Haemoglobin A1c (HbA1c) reflects ambient mean glycaemia over a 2-3 months period. Reports indicate that patients, with and without diabetes, with an elevated HbA1c have an increased risk of adverse outcome following surgical intervention. Our aim was to determine whether elevated plasma HbA1c level was associated with increased postoperative morbidity and mortality in patients undergoing vascular surgical procedures. Methods. Plasma HbA1c was measured prospectively in 165 consecutive patients undergoing emergency and elective vascular surgical procedures over a 6-month period. Patients were categorized into four groups depending on whether their plasma HbA1c was %6%, 6.1-7%, 7.1-8% or O8% and clinical data was entered into a prospectively maintained database. Patients were also classified by diabetic status with suboptimal HbA1c in a patient without diabetes being O6 to %7% and suboptimal HbA1c in a patient with diabetes being O7%. Patients with plasma HbA1c O7% were reclassified as having undiagnosed diabetes mellitus. Composite primary endpoints were all cause 30-day morbidity and mortality and all cause 6-month mortality. Composite secondary endpoints were procedure specific complications, adverse cardiac events, stroke, infection and mean length of hospital stay. Results. Of the 165 patients studied, 43 (26.1%) had diabetes and the remaining 122 (73.9%) did not. The mean age was 72 years and 59% were male. Suboptimal HbA1c levels were found in 58% patients without diabetes and in 51% patients with diabetes. In patients without diabetes those with suboptimal HbA1c levels (6-7%) had a significantly higher incidence of overall 30-day morbidity compared to patients with HbA1c levels %6% (56.5 vs 15.7%, p!0.001). Similarly, for patients with diabetes those with suboptimal HbA1c levels (HbA1c O7%) had a significantly higher incidence of 30-day morbidity compared to those with HbA1c levels %7% (59.1% vs 19%, pZ0.018). Multivariate analysis revealed that a plasma HbA1c level of O6 to %7% was a significant independent predictor of overall 30-day morbidity in patients without diabetes undergoing vascular surgical procedures. No difference in mortality, composite secondary endpoints, procedure specific complications, stroke or mean length of hospital stay was observed between any of the groups in the study. Conclusion. Suboptimal HbA1c levels may hold prognostic significance in patients without diabetes undergoing vascular surgery.
Introduction
Plasma haemoglobin A1c (HbA1c) reflects mean ambient fasting and postprandial glycaemia over a 2-3 months period. HbA1c is formed by the slow irreversible, non-enzymatic glycation of valine and lysine residues in the haemoglobin molecule. 1 It is a useful test for characterising dysglycemia as it is easier to perform than an oral glucose tolerance test and is independent of patient prandial status. 2, 3 Elevated HbA1c levels (O7%) are associated with a higher incidence of microvascular and macrovascular complications in patients with type 1 and type 2 diabetes mellitus. It has been shown conclusively that a reduction in plasma HbA1c levels below 7%, leads to a lower incidence of microvascular complications in both type 1 and type 2 diabetes mellitus. 4, 5 However, the corollary that a reduction in plasma HbA1c levels would lead to a similar reduction in the incidence of macrovascular complications in patients with diabetes failed to reach clinical statistical significance. 4, 5 Currently much attention has been focused on the role of HbA1c in characterising dysglycaemia in patients without diabetes. 2, [6] [7] [8] [9] [10] [11] [12] Recent studies have indicated that patients (both without and without diabetes) with an elevated HbA1c have a higher rate of adverse outcomes following cardiac surgery and percutaneous coronary intervention. 6, 7, 13 Other studies have implicated HbA1c as an independent risk factor for cardiovascular events and the development of atherosclerosis, independent of diabetes status. 9, 14 To our knowledge, there have been no previous studies examining plasma HbA1c levels and outcomes in vascular patients. In this study, we sought to characterise whether a patient's preoperative glycaemia, as reflected by plasma HbA1c, was related to perioperative morbidity, mortality and average length of hospital stay in both non-diabetic and patients with diabetes undergoing vascular surgical procedures.
Methods
Preoperative plasma HbA1c levels were prospectively collected from all patients admitted for a vascular surgery procedure over a 6-month period. Patients admitted for both emergency and elective procedures were included in the study. Those with a history of a recent blood transfusion or a haemoglobinopathy were excluded from the study, as plasma HbA1c measurements in these patients are known to be unreliable. 15 Clinical data was collected and entered into a prospectively maintained database (Vascubase w , Consensus Medical, USA).
The clinical data included in the study were: plasma HbA1c level, risk factors for vascular disease and comorbidities (diabetes mellitus, hypertension, smoking, dyslipidaemia, cardiac risk factors [i.e. previous myocardial infarction, angina pectoris, congestive heart failure, preexisting arrhythmia]), preoperative fasting plasma glucose levels, length of hospital stay (LOS), postoperative morbidity and mortality. The local ethical review board were consulted about this study.
Emergency procedures were included in this study so to avoid selection bias. Samples for plasma HbA1c were collected preoperatively from all patients admitted for acute procedures along with the other routine preoperative bloods. However, fasting blood samples (e.g. for glucose, lipids etc.) were done within 1 week postoperatively in all patients admitted for emergency procedures.
Patients were stratified into four groups based on their plasma HbA1c level: group 1ZHbA1c%6%, group2ZHbA1c 6.1-7.0%, group 3ZHbA1c 7.1-8.0% and group 4ZHbA1c O8%. Patients were further classified as either having or not having diabetes. Patients without diabetes were defined as those without a history of diet or pharmacologically controlled diabetes mellitus, a plasma HbA1c level %7% and a preoperative fasting plasma glucose ! 7.0 mmol/l. 6 Patients with diabetes were defined as those with a history of either type 1 or type 2 diabetes mellitus as given in the medical history on admission, and/or those taking either insulin and/or oral hypoglycaemic agents or two consecutive preoperative fasting plasma glucose levels R7.0 mmol/l. For patients without diabetes, a plasma HbA1c O6 and %7% was considered suboptimal. 6, 15 In contrast, for patients with diabetes, a plasma HbA1c O7% was considered suboptimal.
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HbA1c levels were measured using high pressure liquid chromatography (HPLC), coefficient of variation !1%.
All patients with diabetes were reviewed by a consultant endocrinologist both preoperatively and postoperatively. Preoperatively, patients with diabetes were put on an insulin/dextrose infusion and insulin sliding scale if clinically indicated. Blood sugars were measured routinely by nursing staff using a glucometer and the appropriate dose of insulin was given according to the sliding scale.
Postoperatively, capillary blood glucose levels were monitored 2-4 times daily on all patients with diabetes by nursing staff using a glucometer. These blood sugar levels were monitored daily by a consultant endocrinologist or by a member of the endocrinology team and the appropriate measure (e.g. diet, oral hypoglycaemic, insulin, sliding scale) was implemented to try and maintain blood sugar in the range 4-6 mmol/l.
Those newly diagnosed with diabetes were referred to the endocrinology service for a comprehensive assessment.
Endpoints
The composite primary endpoints for the study were all cause 30-day morbidity and mortality and all cause 6-month mortality. The composite secondary endpoints were procedure specific complications, stroke, adverse cardiac events (cardiac arrest, myocardial infarction, pulmonary oedema), infection and mean length of hospital stay. Adverse cardiac events were detected by postoperative monitoring of patients for clinical symptoms of chest pain, palpitations and shortness of breath or unresponsiveness. Serial 12-lead Haemoglobin A1c (HbA1C) in Non-diabetic and Diabetic Vascular Patients electrocardiograms, cardiac enzymes and troponins were performed on all postoperative patients, regardless of symptoms. A clinical history of shortness of breath and/or orthopnoea and/or paroxysmal nocturnal dyspnoea with suggestive chest X-ray changes was used to diagnose pulmonary oedema. All patients were followed up 6 months after the study period to assess endpoints.
Statistical analysis
All data were analysed using SPSS w Version 12.0.1. Continuous variables were analysed by two groups only using 2-tailed t-testing and between more than two groups by using ANOVA followed by posthoc testing with Tukey HSD. Categorical variables were analyzed with the chi-square or Fisher exact test, where appropriate. All baseline characteristics, risk factors and co-morbidities were analyzed to determine the univariate predictors of overall 30-day postoperative morbidity. All univariate variables with a p-value of !0.25 were entered into a stepwise multiple logistic regression analysis. Age and sex were included regardless of the p-value. A p-value of ! 0.05 was assumed to represent statistical significance. Baseline characteristics for all patients in the study are given in Table 1 and Table 2 shows the procedures performed.
Results

From
Plasma HbA1c group distribution
Plasma HbA1c distribution among the different groups is shown in Fig. 1 . Among patients without diabetes, 62 (50.8%) patients had suboptimal (HbA1c O6 and %7%) preoperative plasma HbA1c levels and 51 (41.8%) patients had optimal preoperative plasma HbA1c level (HbA1c %6%). Nine patients (7.4%) who were originally categorized as not having diabetes mellitus had a plasma HbA1c O7%. These patients were subsequently reclassified as having undiagnosed diabetes mellitus, fasting plasma glucose levels confirmed their status. Among the patients with diabetes, 21 patients (48.8%) had optimal preoperative plasma HbA1c levels (HbA1c %7%) and 22 patients (51.2%) had suboptimal plasma HbA1c levels (HbA1c O7%).
Composite primary endpoints
The all-cause 30-day morbidity rate for groups 1-4 is shown in Fig. 2 . Among patients without diabetes, those with HbA1c levels of 6.1-7% had a significantly higher incidence of all-cause 30-day morbidity compared to patients with HbA1c levels %6% (56.5% vs 15.7%, 95% CI Z2.8-17.2, RR 7.0, p!0.001).
Similarly among patients with diabetes, patients with HbA1c levels O7% also had a significantly higher incidence of all-cause 30-day morbidity compared to patients with HbA1c levels %7% (59.1% vs 19%, 95% CI 1.5-24.4, RR 6.1, pZ0.018). No significant differences in 30-day or 6 month mortality were observed among any of the groups.
Comparison of patients with and without diabetes
Comparisons of 30-day morbidity rates for patients with and without diabetes are shown in Fig. 5 . There was no significant difference between patients without diabetes with plasma HbA1c levels between 6.1 and 7% and patients with diabetes mellitus (56.5% vs 39.5%, pZ0.1). However, a significant difference was observed between patients without diabetes with plasma HbA1c levels %6% and patients with diabetes mellitus (15.7% vs 39.5%, 95% CI 1.3-9.3, RR 3.5, pZ 0.018). These results would appear to suggest that an adverse outcome is more dependent on the preoperative plasma HbA1c level than on the diabetes status of the patient.
Comparison of types I and II diabetes mellitus
No significant differences in all cause 30-day morbidity (30% vs 42.4%, pZ0.7), 6-month mortality (10% vs 3%, pZ0.9) or length of hospital stay (22.7 days vs 25.03 days, pZ0.7) were observed between patients Non-diabetics with type 1 (nZ10) and type 2 (nZ33) diabetes mellitus.
Composite secondary endpoints
There was a significantly higher incidence of adverse cardiac events among patients without diabetes with preoperative plasma HbA1c levels between 6.1 and 7% undergoing aortic procedures (35% vs 0%, pZ0.012).
There was also an overall higher incidence of postoperative infection (21.1% vs 5.9%, pZ0.037), particularly postoperative wound infection (9.9% vs 0%, p! 0.05) among patients without diabetes with preoperative plasma HbA1c levels between 6.1 and 7%. No significant differences in the other secondary endpoints of procedure specific complications, stroke, or mean length of hospital stay (Fig. 4) were observed between the groups.
Procedure specific endpoints
The all-cause 30-day morbidity rate for all procedures and each individual procedure (i.e. carotid, aortic, peripheral artery and amputation) among patients without diabetes is shown in Fig. 3 . Patients without diabetes who underwent peripheral arterial surgery and aortic surgery with a preoperative plasma HbA1c 6.1-7% had a significantly higher all-cause 30-day postoperative morbidity than patients with a preoperative plasma HbA1c %6% (aortic surgery: 50% vs 6.7%, RR 14.0, 95% CI 1.5-130, pZ0.009, peripheral arterial surgery: 77.8% vs 20%, RR 14, 95% CI 2.6-75.4, pZ0.004). No significant differences in all-cause 30-day morbidity were observed in the carotid artery and amputation procedure subgroups (Fig. 5) .
A total of 36 patients underwent aortic procedures in this study. The aortic procedures comprised 18 patients in the EVAR group and 18 patients in the open AAA group. Only one patient 1/36 had diabetes (type II) with an optimal HbA1c level (HbA1cZ6.4%). A total of 19/36 patients in the aortic procedure group had suboptimal HbA1c levels. Nine of the nineteen underwent an EVAR procedure and 10/19 underwent an open AAA repair. When these two groups were compared, there was no significant difference in overall 30-day morbidity (55.6% (EVAR) vs 50%, pZ1.0) or 6-month mortality (11.1% vs 10%, pZ1.0) ( Table 5) .
When peripheral arterial bypass was compared to peripheral artery angioplasty and arterial embolectomy there was no significance difference in overall 30-day morbidity (for those without diabetes, pZ0.9, for those with diabetes, pZ0.3), 6-month mortality (without diabetes, pZ1.0, with diabetes, pZ0.9) or length of hospital stay (without diabetes, pZ0.06, with diabetes, pZ0.07). When carotid endarterectomy was compared with carotid artery stenting technique there was no significant difference in overall 30-day mortality (without diabetes, pZ0.9, with diabetes, pZ1.0), 6-month mortality (no deaths either group) or length of hospital stay. When major amputations were compared to minor amputations there was also no significant difference in overall 30-day mortality, 6 month mortality or length of hospital stay.
Predictors of postoperative morbidity
Univariate and multivariate analyses for all patients and patients without diabetes, respectively, are shown in Tables 3 and 4 , respectively. Univariate analysis was performed with 30-day morbidity as the dependent variable and risk factors for adverse outcome, including plasma HbA1c as the independent variables. Univariate predictors of adverse outcome among all patients were plasma HbA1c 6.1-7%, plasma HbA1c O8% and diabetes mellitus. Plasma HbA1c O6 and %7% was the only univariate predictor of 30-day morbidity to reach statistical significance among patients without diabetes. Surprisingly, among patients with diabetes, no univariate predictors of 30-day postoperative morbidity were identified.
Discussion
This prospective cohort study, which included 122 patients without diabetes and 43 patients with diabetes, set out to determine whether or not patients with and without diabetes with suboptimal HbA1c levels had a worse postoperative outcome than those patients with optimal HbA1c levels in a vascular surgical population. We found that both non-diabetic and patients with diabetes with suboptimal HbA1c levels had significantly higher 30-day postoperative morbidity rates than non-diabetic and patients with diabetes with optimal plasma HbA1c levels. Among patients without diabetes, a plasma HbA1c O6 and %7% was found to be a significant independent predictor of overall 30-day postoperative morbidity. Therefore, a suboptimal HbA1c level may hold prognostic significance in patients without diabetes undergoing vascular surgery.
It is has been suggested that diabetes mellitus represents just 'the measured tip of a much larger 'dysglycemic iceberg''. 9 Raised glucose levels in the circulation may speed up the process of atherosclerosis through putative mechanisms such as oxidative stress and protein glycation of vessel walls. 17 In patients with diabetes, reducing plasma HbA1c levels by tight glycaemic control lowers the risk of subsequent microvascular disease. However, the relation of reduced HbA1c levels with macrovascular outcomes (e.g. stroke, ischaemic heart disease, peripheral vascular disease) is less clear. 5 Studies have concluded that a progressive relation between glucose concentrations and cardiovascular disease extends below the current threshold used to define diabetes mellitus. 10, 18 Therefore, patients without diabetes with suboptimal HbA1c levels may have a level of dysglycaemia that may not meet the criteria for a diagnosis of diabetes mellitus, but may still contribute to an adverse postoperative outcome. Plasma HbA1c would be a more useful test for trying to identify these patients preoperatively than other tests, such as fasting plasma glucose level or an oral glucose tolerance test). 3 Although some studies have shown an association between abnormalities in fasting glucose below the diabetes threshold and poor cardiovascular outcome, [19] [20] [21] in general there is a lack of conclusive data relating fasting hyperglycaemia to cardiovascular risk. 22, 23 Furthermore, other studies have indicated that postprandial hyperglycemia may have more prognostic significance in terms of cardiovascular outcome compared with fasting hyperglycemia. [24] [25] [26] However, diagnostic testing of postprandial plasma glucose levels is cumbersome. HbA1c levels, on the other hand, provide a simple, single-sample determination, that is reflective of both fasting and postprandial glycaemia. We did not perform an oral glucose tolerance test (OGTT) on any of the patients included in our study as it was deemed too time consuming and involved the patients receiving two episodes of phlebotomy (one preprandial and one 2 h postload glucose) instead of just one. We, therefore, only collected blood samples for HbA1C and we collected fasting plasma glucose levels from each of the patients as outlined in the methods section in the paper. An advantage of HbA1C levels was that they gave an indication of chronic hyperglycaemia. The average time-period plasma HbA1c levels were taken prior to surgery among the 165 patients included in the study was 5.47 days (standard deviation 4.45). A long time period between testing and surgery was arbitrarily chosen as O5 days and %16 days. There was no significant difference in the predictive value in those with a long time period between testing and surgery (i.e. O5 days and %16 days) and those with a short time period between testing and surgery (i.e. %5 days). When univariate analysis was performed in all patients who had plasma HbA1c levels measured %5 days prior to surgery, a plasma HbA1c level O6 and %7% was a significant independent predictor of overall 30-day postoperative morbidity (odds ratio (OR) 4.8, 95% confidence interval (CI) 1.4-16.8, pZ0.015) as was a plasma HbA1c O8% (OR 80.1, 95% CI 6.9-921.0, p! 0.001). When univariate analysis was performed in all patients who had plasma HbA1c levels measured O5 and %16 days prior to surgery (i.e. a long time period between testing and surgery, plasma HbA1c level O6 and %7% remained a significant independent 13 In comparison, 13.7% of non-diabetics with optimal HbAlc levels (HbA1c%6%) had impaired glucose tolerance (as defined by the American Diabetic Association). There was no significant difference between these two groups (pZ0.7) impaired fasting glucose was not predictive of an adverse outcome. However, we did find that suboptimal HbA1c levels were associated with an adverse postoperative outcome.
In our study, over half of the patients without diabetes (50.8%) presenting for vascular surgical procedures had chronic hyperglycaemia as reflected by suboptimal plasma HbA1c levels. Similarly, over half of the patients with diabetes (51.2%) presenting for vascular surgical procedures had suboptimal HbA1c levels (HbA1c O7%) as defined by the ADA. In a study on HbA1C levels in patients without diabetes under going percutaneous coronary revascularisation, Corpus et al. 6 found that the incidence of an abnormal haemoglobin A1c level (i.e. O6%) was approximately 32%. This was explained by many of the characteristics of the insulin-resistant state such as obesity, dyslipidemia, and hypertension, which also are risk factors for atherosclerosis. They also postulated that the first clinical manifestation of this 'prediabetic state' is coronary artery disease. In addition Lauruschkat et al., 27 in a study of 7310 patients undergoing coronary artery bypass grafting found that those with undiagnosed diabetes had the poorest outcome. The authors concluded that the presence of more cardiac-type risk factors than peripheral arterial vascular risk factors suggested a briefer duration of the disease, which might in turn explain the occult diagnosis. This was made all the more likely by the fact that type 2 diabetes is often diagnosed with a delay of as much as 7 years after the actual onset of the disease. This may well explain why HbA1C levels in our study of vascular patients were greater than those in cardiac studies.
We found no significant difference in 30-day postoperative morbidity between patients with and without diabetes. When patients without diabetes with suboptimal HbA1c levels (HbA1c 6-7%) were compared with patients with diabetes there was no significant difference in postoperative morbidity. However, there was a significant difference in 30-day postoperative morbidity between patients without diabetes with optimal HbA1c levels (HbA1c %6%) and patients with diabetes. Hence, the diabetes status of the patient may be less important in determining postoperative outcome than the preoperative plasma HbA1c level (similarly the diagnosis of dyslipidaemia is less important than the actual fasting plasma lowdensity lipoprotein cholesterol level in determining cardiovascular risk). A previous study by Khaw et al.
2 demonstrated that a raised HbA1c predicted mortality and cardiovascular disease in patients without diabetes in the community. They found that an increase in HbA1c of 1% was associated with a 20-30% increase in mortality or cardiovascular events. 2 It was thought that HbA1c resembles blood pressure or cholesterol in terms of the continuous relation with cardiovascular risk. However, in our study, although patients with suboptimal HbA1c levels did have a higher mortality rate than those with optimal HbA1c levels, the differences were not statistically significant. The reasons for this are unclear. It may be due to the fact that all of our patients are treated aggressively preoperatively by high-dose (80 mg) atorvastatin, with a cardio-selective betablocker and aspirin. For patients with ischaemic heart disease we add amlodipine. All patients are commenced on clopidegrol postoperatively. 28 As the mortality rate in our study was overall relatively low (5.5%), larger studies over a longer time period may be required to find any appreciable significant difference in mortality rates. Previous studies on cardiac patients undergoing coronary bypass grafting have reported a rise in hospital mortality rates of patients with diabetes and of previously undiagnosed patients with diabetes. 29, 30 Remarkably, the highest mortality rate was found among the group of patients with undiagnosed diabetes.
Previous major studies, comparing bypass surgery with interventional cardiology (PTCA/stenting), have reported that in the 5-year survival, there were no significant differences between these therapy strategies. 31 However, in the bypass angioplasty revascularization investigation (BARI) the infarction mortality rate in the subgroup of patients with diabetes mellitus assigned to the coronary surgery group was significantly lower than that in the PTCA group. 32 Later studies [33] [34] [35] confirmed that coronary surgery leads to significantly better results in patients with diabetes. However, in all these studies the 'diabetes mellitus' status was acquired only under categorical terms. Patients were deemed as having diabetes according to the admission diagnosis based on information given by the patient and documented use of oral anti-diabetic agents or insulin therapy. Hence, inclusion of those with occult diabetes in the group without diabetes could have biased results. We found no significant difference between open and endovascular procedure results.
In conclusion, we found that the half of patients without diabetes presenting for vascular surgery had chronic hyperglycaemia, as determined by plasma HbA1c O6 and %7%,. Similarly half of the patients with diabetes presenting for vascular surgery had suboptimal HbA1c levels (HbA1c O7%). Both patients with and without diabetes with suboptimal HbA1c levels had a higher incidence of 30-day postoperative morbidity compared to those with optimal HbA1c levels. Multivariate analysis revealed that in patients without diabetes, a plasma HbA1c O6 and %7% was a significant independent predictor of overall 30-day morbidity. A suboptimal HbA1c level, therefore, may have prognostic significance in patients without diabetes undergoing vascular surgery.
